Abstracts tagged "Patient reported outcomes"

Abstract Number: 0941 • ACR Convergence 2020
MDHAQ/RAPID3 (multidimensional Health Assessment Questionnaire/routine Assessment of Patient Index Data) Levels Are Elevated in Rheumatology Patients Who Meet 2011 Fibromyalgia (FM) or MDHAQ/FAST3 (fibromyalgia Assessment Screening Tool) Criteria
Juan Schmukler¹, Tengfei Li², Kyle Schroeder³ and Theodore Pincus³, ¹Mount Sinai Hospital Chicago, IL, Chicag, IL, ²Georgetown University, Washigton, ³Rush University Medical Center, Chicago, IL
Background/Purpose: RAPID3 (routine assessment of patient index data) on an MDHAQ (multiple multidimensional health assessment questionnaire) was developed initially to assess patients with rheumatoid arthritis…
Abstract Number: 1216 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, and Health Related Quality of Life, and Reduced Fatigue over Time in Patients with Rheumatoid Arthritis Who Are Methotrexate-Naïve: Results from a Phase 3 Study
Rieke Alten¹, William F. C. Rigby², Alena Pechonkina³, Zhaoyu Yin⁴, Ken Hasegawa⁴, Thijs Hendrikx⁵, Tatsuya Atsumi⁶ and Rene Westhovens⁷, ¹Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Gilead Sciences, Inc., Foster City, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan, ⁷University Hospitals Leuven, Belgium, Leuven, Belgium
Background/Purpose: In FINCH 3, filgotinib (FIL)—a potent, selective, oral JAK1 inhibitor1—in combination with methotrexate (MTX), demonstrated significant improvements in signs and symptoms of rheumatoid arthritis…
Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Laura Coates¹, Désirée van der Heijde², Lars Erik Kristensen³, William Tillett⁴, Jason Eells⁵, Tommi Nurminen⁶ and Atul Deodhar⁷, ¹University of Oxford, Oxford, United Kingdom, ²Leiden University Medical Center, Leiden, Netherlands, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…
Abstract Number: 1616 • ACR Convergence 2020
Systematic Review of Effectiveness Outcomes Reported in Rheumatology Transition Literature
Heather Bannerman¹, Karen Beattie¹, Avanti Patel², Milica Tanic², Michelle Batthish³ and Mark Matsos², ¹McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada
Background/Purpose: In young patients with rheumatologic disease, transition from pediatric to adult care is a complex process. Poor transitional care leads to health deterioration, loss…
Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Jing Xue¹, Hongzhi Wang², Hongbin Li³, Hui Song⁴, Yasong Li⁵, Xiaofei Shi⁶, Hongjun Zhao⁷, Feng Wei⁸, Bing Wu⁹, Hui Xiao¹⁰, Yuhua Jia⁹, Fei Xiao⁹ and Huaxiang Wu¹, ¹The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, China (People's Republic), ²The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ³The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ⁴Beijing Jishuitan Hospital, Beijing, China (People's Republic), ⁵Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of science and technology, Luoyang, China (People's Republic), ⁷Xiangya Hospital of Central South University, Changsha, China (People's Republic), ⁸Jiangmen Central Hospital Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China (People's Republic), ⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…
Abstract Number: 0151 • ACR Convergence 2020
More Than Half of Newly Diagnosed RA Patients Are Not Convinced of the Necessity of RA Medicines: Associations with RA Characteristics, Symptoms, and Function in the Canadian Early Arthritis Cohort (CATCH)
Viviane Ta¹, Orit Schieir², Marie-France Valois³, Diane Tin⁴, Carol Hitchon⁵, Louis Bessette⁶, Carter Thorne⁴, Janet Pope⁷, Gilles Boire⁸, Edward Keystone⁹, Vivian Bykerk¹⁰, Susan Bartlett³ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹McGill University, Montreal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Southlake Regional Health Centre, Newmarket, ON, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Laval University, Quebec, Canada, ⁷Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁸Universite de Sherbrooke, Sherbrooke, Canada, ⁹The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Although DMARDs are essential for early aggressive control of RA to reduce symptoms and disability, medication adherence is variable. Beliefs about the necessity of…
Abstract Number: 0276 • ACR Convergence 2020
Type 2 SLE Symptoms Persist Despite Type 2 Medication Polypharmacy
Raeann Whitney¹, Amanda Eudy², Cynthia Coffman³, Megan Clowse⁴, Lisa Criscione-Schreiber⁵, Jayanth Doss², Rebecca Sadun², Kai Sun² and Jennifer Rogers⁶, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke University, Chapel Hill, NC, ⁵Duke University School of Medicine, Durham, NC, ⁶Duke, Durham, NC
Background/Purpose: Management of Type 2 SLE (widespread pain, fatigue, depression, sleep distrubance, and cognitive dysfunction) is challenging and often requires multiple medications to ameliorate symptoms.…
Abstract Number: 0535 • ACR Convergence 2020
Provider Opinion and Support for Shared Decision-making in Gout Treatment: A Quality Improvement National Survey of Veterans Affairs Rheumatologists
Jasvinder Singh¹, John Richards², Elizabeth Chang³, Toupin-April, Karine Toupin-April⁴ and Jennifer Barton⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ³Phoenix VA Medical Center, Phoenix, AZ, Phoenix, AZ, ⁴VA Portland Oregon, Portland, OR, ⁵Oregon University, Portland, OR
Background/Purpose: To assess rheumatologists’ views and practices related to shared decision making (SDM) in gout treatment.Methods: We performed a cross-sectional electronic survey of rheumatologists at…
Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Frank Behrens¹, Ulrich Prothmann², Thilo Klopsch³, Ann-Dörthe Holst⁴, Lisa Blindzellner⁵, Olaf Behmer⁵, Pascal Klaus⁵, Thomas Meng⁵ and Peter-Andreas Löschmann⁵, ¹CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ²Knappschaftsklinikum Saar, Püttlingen, Saarland, Germany, ³Rheumatological Practice, Neubrandenburg, Mecklenburg-Vorpommern, Germany, ⁴Specialist Practice for General Medicine incl. Rheumatology and Acupuncture, Ludwigslust, Mecklenburg-Vorpommern, Germany, ⁵Pfizer Pharma GmbH, Berlin, Berlin, Germany
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…
Abstract Number: 1218 • ACR Convergence 2020
Filgotinib Provided Rapid and Sustained Improvements in Functional Status, Pain, Health-related Quality of Life, and Fatigue in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Alan Kivitz¹, Yoshiya Tanaka², Susan Lee³, Lei Ye³, Hao Hu³, Robin Besuyen⁴ and Bernard Combe⁵, ¹Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵University of Montpellier, Montpellier, France
Background/Purpose: In the FINCH 1 study, filgotinib (FIL)—an oral, potent, selective JAK1 inhibitor—plus methotrexate (MTX) provided significant improvements in signs and symptoms of rheumatoid arthritis…
Abstract Number: 1363 • ACR Convergence 2020
Efficacy of Secukinumab on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Post Hoc Analysis from a Phase 3 Trial
Vibeke Strand¹, Gurjit Kaeley², Martin Bergman³, Dafna Gladman⁴, Laura Coates⁵, Peter Hur⁶, Nina Kim⁷, Bhumik Parikh⁶, Patricia Pertel⁸ and Philip Mease⁹, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Florida College of Medicine - Jacksonville, Jacksonville, FL, ³Drexel University College of Medicine, Philadelphia, PA, ⁴Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Oxford, Oxford, United Kingdom, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁸Novartis AG, Basel, Switzerland, ⁹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: The phase 3 randomized controlled trial FUTURE 5 (NCT02404350) showed the efficacy of secukinumab (SEC) improving clinical signs, symptoms, and radiographic progression in patients…
Abstract Number: 1632 • ACR Convergence 2020
Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Joerg Henes¹, Norbert Blank², Michael Borte³, Ivan Foeldvari⁴, Gerd Horneff⁵, Markus Hufnagel⁶, Tilmann Kallinich⁷, Birgit Kortus-Goetze⁸, Catharina Schuetz⁹, Frank Weller-Heinemann¹⁰, Julia Weber-Arden¹¹ and Jasmin Kuemmerle-Deschner¹², ¹Department of Internal Medicine II, Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Department of Hematology, Oncology and Rheumatology, Internal Medicine V, University Hospital of Heidelberg, Eppelheim, Germany, ³ImmunoDeficiencyCenter Leipzig (IDCL), Hospital St. Georg gGmbH Leipzig, Germany, Leipzig, Germany, ⁴Head of the Hamburg Centre for Pediatric and Adolescence Rheumatology, Budapest, Hungary, ⁵Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁶Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center, Medical Faculty, University of Freiburg, Germany, Freiburg, Germany, ⁷Charite, Berlin, Germany, ⁸Division of Nephrology, University of Marburg, Germany, Marburg, Germany, ⁹Department of Pediatric Immunology, University Hospital Dresden, Dresden, Germany, Dresden, Germany, ¹⁰Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, Bremen, Germany, ¹¹Novartis Pharma GmbH, Nuremberg, Germany, ¹²University Hospital Tuebingen, Tuebingen, Germany
Background/Purpose: Autoinflammatory periodic fever syndromes characterized by excessive interleukin(IL)-1ß release and severe systemic and organ inflammation have been successfully treated with the anti-IL-1ß inhibitor canakinumab.…
Abstract Number: 1943 • ACR Convergence 2020
The Prevalence of Anxiety and Depression in Patients with Giant Cell Arteritis
Joana Martinho¹, André Ponte², Eduardo Dourado³, Nikita Khmelinskii¹, Sara Dias⁴, Sofia Barreira⁵, Ana Rita Cruz-Machado¹, Carla Macieira¹, Vítor Teixeira⁶, Ana Rodrigues⁴, Diogo Telles-Correia⁷, João Eurico Fonseca⁸ and Cristina Ponte¹, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ²Centro Hospitalar Psiquiátrico de Lisboa, Lisboa, Portugal, Lisbon, Portugal, ³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Lisboa, Portugal, ⁴EpiDoC Unit, Centro de Estudos de Doenças Crónicas (CEDOC), NOVA Medical School, Universidade NOVA de Lisboa (NMS/UNL), Lisbon, Portugal, ⁵Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, ⁶Rheumatology Department, Centro Hospitalar Universitário do Algarve, Faro, Portugal, ⁷Serviço de Psiquiatria, Hospital de Santa Maria, CHULN, Lisboa, Portugal, Lisbon, Portugal, ⁸Instituto de Medicina Molecular, Faculdade Medicina Universidade de Lisboa and Centro Hospitalar Universitário Lisboa Norte., Lisboa, Portugal
Background/Purpose: Giant cell arteritis (GCA) is the most common primary vasculitis of the elderly causing blindness if left untreated. However, its hallmark treatment with glucocorticoids…
Abstract Number: 0152 • ACR Convergence 2020
Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
Swathi Reddy¹, Aricca Van Citters², Rashmi Arora¹, Kyawt Shwin¹, Lisa Johnson², Jabeen Ahmad², Guy Eakin³, Eugene Nelson², Andreas Reimold¹ and Salahuddin Kazi¹, ¹Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ²The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, ³Arthritis Foundation, Atlanta, GA
Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…
Abstract Number: 0280 • ACR Convergence 2020
Compliance and Validation of Patient Reported Outcome Information Collected from Lupus Patients Using a Mobile Application
Kristy Bell¹, Claire Dykas¹, Hope Rainey¹, Maggy Comberg¹, Mary Mora¹ and Peter Lipsky¹, ¹AMPEL BioSolutions LLC., Charlottesville, VA
Background/Purpose: Patient Reported Outcomes (PROs) can provide critical data in measuring the impact of a disease on an individual as well as the quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.